Dr. Philip Kuriakose, MD
Claim this profileHenry Ford Health System
Affiliated Hospitals
Henry Ford Health System
Henry Ford Hospital
Clinical Trials Philip Kuriakose, MD is currently running
Natural History Study
for Blood Disorders
In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5 In 2019 alone, the FDA has issued approvals for 24 new therapies for congenital and acquired hematologic conditions.6 In addition, almost 10,000 new studies for hematologic diseases are currently registered on www.clinicaltrials.gov.7 With this increase in potential new therapies possible, it is imperative that clinicians and clinical researchers in the field of non-neoplastic hematology have a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data. As emphasized in a recently published review, accurate, uniform and quality national data collection is critical in clinical research, particularly for longitudinal cohort studies covering a lifetime of biologic risk.8
Recruiting
1 award
N/A
1 criteria
SEVENFACT®
for Hemophilia
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Recruiting
3 awards
Phase 4
6 criteria
More about Philip Kuriakose, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Philip Kuriakose, MD has experience with
- Brentuximab Vedotin
- Nivolumab
- Rituximab
- Cyclophosphamide
- Recombinant Von Willebrand Factor
- Tranexamic Acid
Breakdown of trials Philip Kuriakose, MD has run
Hemophilia
Hemophilia A
Hemophilia B
Von Willebrand Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Philip Kuriakose, MD specialize in?
Philip Kuriakose, MD focuses on Hemophilia and Hemophilia A. In particular, much of their work with Hemophilia has involved treating patients, or patients who are undergoing treatment.
Is Philip Kuriakose, MD currently recruiting for clinical trials?
Yes, Philip Kuriakose, MD is currently recruiting for 4 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Philip Kuriakose, MD has studied deeply?
Yes, Philip Kuriakose, MD has studied treatments such as Brentuximab Vedotin, Nivolumab, Rituximab.
What is the best way to schedule an appointment with Philip Kuriakose, MD?
Apply for one of the trials that Philip Kuriakose, MD is conducting.
What is the office address of Philip Kuriakose, MD?
The office of Philip Kuriakose, MD is located at: Henry Ford Health System, Detroit, Michigan 48202 United States. This is the address for their practice at the Henry Ford Health System.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.